Pelthos Therapeutics Inc. (PTHS) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Pelthos Therapeutics Inc. (NYSE: PTHS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $9.40 (-43.17% 1D, market cap $63.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PTHS ranks #717 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PTHS carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 76.3%, and ROIC of -35.0%. By comparison, CSBR (Champions Oncology Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -26.9%, cap $66.9M) and CGTX (Cognition Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M). Among the 5-stock peer group, PTHS leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).
Per PTHS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001919246), Pelthos Therapeutics Inc. generated $16.8M in revenue, -$43.3M in net income, and -$22.7M in free cash flow against $130.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 21.8 (OVERSOLD (<32))
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While PTHS currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.36) and Max Pain ($9.87) forces dealer call-delta covering toward $39.38.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Pelthos Therapeutics Inc. (PTHS) dropped -43.17% to $9.40, trading at 2% of its 52-week range ($9.02 – $37.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
citybiz report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
The Pharma Letter report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
The agreement provides for up to $300m in milestone payments, including $50m tied to specified Phase III clinical endpoints.
Strategic Combination Brings Highly Innovative Late-Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug-Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB) Combines Two Complementary Platforms
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PTHS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PTHS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Pelthos Therapeutics Inc. (PTHS) ranks #717 by composite RQD confidence (34/100, grade E) and #721 by equity capitalization ($63.3M). Within this direct 5-issuer industry benchmark cohort, PTHS leads on earnings valuation at N/A trailing P/E, while CSBR leads on capital efficiency and profitability with -26.9% ROIC and 48.0% gross margin. CGTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with PTHS at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PTHS
ACTIVE
Pelthos Therapeutics Inc. | E | 34/100 | — | 76.3% | -35.0% | -43.17% | $63.3M | Benchmark Subject |
| CSBR Champions Oncology Inc. | E | 22/100 | — | 48.0% | -26.9% | 0.00% | $66.9M | /csbr-vs-pths → |
| CGTX Cognition Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | -5.57% | $70.3M | /cgtx-vs-pths → |
| GRML Greenland Mines Ltd. | E | 32/100 | — | — | -35.0% | -10.89% | $70.3M | /grml-vs-pths → |
| CRDF Cardiff Oncology Inc. | D- | 41/100 | — | — | -35.0% | -2.46% | $70.9M | /crdf-vs-pths → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pelthos Therapeutics Inc. (PTHS) reported GAAP revenue of $16.8M (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$43.3M, operating cash flow of -$22.6M, and free cash flow of -$22.7M (-291.7% YoY). On the balance sheet, PTHS closed FY2025 with $130.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $16.8M | -$43.3M | -$22.6M | -$22.7M | $130.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$8.0M | -$5.8M | -$5.8M | $1.4M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$7.4M | -$981.0K | -$981.0K | — | — |
As of 2026-11-02, Pelthos Therapeutics Inc. (NYSE: PTHS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $9.40 (-43.17% 1D, market cap $63.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PTHS ranks #717 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PTHS carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 76.3%, and ROIC of -35.0%. By comparison, CSBR (Champions Oncology Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -26.9%, cap $66.9M) and CGTX (Cognition Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M). Among the 5-stock peer group, PTHS leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).
Per PTHS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001919246), Pelthos Therapeutics Inc. generated $16.8M in revenue, -$43.3M in net income, and -$22.7M in free cash flow against $130.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PTHS last traded at $9.40 (-43.17% on volume of 242,070 shares), positioning the stock -55.99% below its 50-day simple moving average ($21.36) and -61.14% below its 200-day simple moving average ($24.19). Across its 52-week range of $9.02 to $37.50, PTHS sits at the 1.3% percentile with a 14-day RSI of 21.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($8.22 to $10.58).
Why PTHS Stock dropped -43.17% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, PTHS scores 34 out of 100, earning an E grade labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
For a prospective investor evaluating the stock today, the implication is that the rating's weakest inputs are cash generation and balance-sheet forensics, which are the components most directly tied to downside risk. The 3/20 cash-engine score and 0% FCF yield mean the valuation rests on expectations of future cash generation rather than current cash flow. The 5/20 forensic score amplifies this concern. Upside drivers would have to come from pipeline or commercial execution rather than the existing financial base. The 12/20 whale-flow score is the strongest pillar, but it does not offset the fundamental and forensic weaknesses, and it should be weighed against the 3/20 insider score.
Pelthos Therapeutics Inc. is a NYSE-listed issuer in the Health Care sector, classified under Biotechnology: Biological Products (No Diagnostic Substances), per the company profile. Per the recent news wire, the company's commercial product is referred to as Zelsuvmi, and its launch estimates were recently cut by analysts. The source data does not specify the customer base, geographic reach, or detailed revenue model. Reported FY 2025 revenue is $16.8M, indicating a commercial revenue stream exists alongside substantial operating losses.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $16.8M | $-32.4M | $-43.3M | N/A | $-22.7M | $18.0M | N/A |
| FY 2024 | $0.0M | $-7.6M | $-8.0M | N/A | $-5.8M | $0.5M | N/A |
| FY 2023 | $0.0M | $-6.9M | $-7.4M | N/A | $-1.0M | N/A | N/A |
Per the SEC financials, the company moved from zero reported revenue in FY 2023 and FY 2024 to $16.8M in FY 2025, while net losses widened from $-7.4M to $-43.3M over the same span. Gross margin is 76.3%, but operating margin and net margin are both -60%, and ROIC is -35%. The source data reports an Altman Z-Score of 0.2 and a Piotroski F-Score of 3 out of 9 within the forensic pillar of the RQD rating. Debt/Equity is 0.5. Reported cash rose to $18.0M in FY 2025 from $0.5M in FY 2024, while FCF remained deeply negative.
The price change of -43.17% and the 52-week range of $9.02 to $37.5 are consistent with the sequence of negative catalysts described. The butterfly supply-chain graph contains no links or proprietary signals.
Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. The source data therefore does not establish upstream suppliers, downstream customers, or cross-company dependencies. For a prospective investor, the key ripple to monitor is the Castle Creek merger and its milestone structure, since any change in the merger's status or milestone achievement would affect the company's capital position and strategic direction. Commercial performance of Zelsuvmi is the second-order driver to track, given the analyst estimate cut. Supply-chain-level bottlenecks cannot be assessed from the source data.
Real-time company headlines, analyst actions, and sector developments for Pelthos Therapeutics Inc. (PTHS) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
citybiz report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
The Pharma Letter report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Pelthos Therapeutics Inc. (PTHS) market action, institutional positioning, and fundamental catalysts.
Welcome to the PTHS (Pelthos Therapeutics Inc.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on PTHS, but look at what you are paying: current EV/EBITDA multiples with 76.3% gross margins. Unless Pelthos Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on PTHS, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $9.40 (52-wk range $9.02 - $37.50), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).